 EMERYVILLE, Calif., Oct. 4, 2021 PRNewswire -- Dynavax Technologies Corporation Nasdaq: DVAX, a biopharmaceutical company focused on developing and commercializing vaccines, and the U.S. Department of Defense DOD today announced Dynavax has executed an agreement for approximately 22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018. 